Mirae Asset cuts Gland Pharma stake to 2.95% after open market sale
- Mirae Asset Mutual Fund sold 57,842 Gland Pharma shares on September 28, 2026
- Stake reduced from 2.99% to 2.95% of total equity capital
- Remaining holding stands at 4,872,191 shares
- Sale executed through the open market

*this image is generated using AI for illustrative purposes only.
Gland Pharma Limited saw a reduction in institutional holding as Mirae Asset Mutual Fund sold 57,842 shares in the open market on September 28, 2026. The disposal lowered the fund's equity stake from 2.99% to 2.95%.
The transaction was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Mirae Asset Investment Managers (India) Private Limited confirmed the sale via a filing to the Bombay Stock Exchange on September 29, 2026.
Transaction details
The fund reduced its position through an open market sale, with no changes to the company's total share capital or diluted voting capital resulting from the trade. The following table outlines the shift in holdings:
| Metric | Before Sale | After Sale | Change |
|---|---|---|---|
| Shares held | 4,930,033 | 4,872,191 | -57,842 |
| % of total capital | 2.99% | 2.95% | -0.04% |
| % of diluted capital | 2.96% | 2.92% | -0.03% |
What the numbers show
The reduction represents a marginal adjustment rather than a significant exit. The fund retains a substantial block of 4,872,191 shares, maintaining its status as a notable non-promoter holder. The dilution impact is minimal, with the stake against diluted share capital falling by only 0.03% to 2.92%, indicating the sale did not materially alter the ownership structure relative to potential convertible instruments.
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.02% | -0.59% | +0.39% | +68.17% | +45.12% | -21.95% |
How might this marginal reduction by Mirae Asset influence the broader institutional sentiment and trading volume for Gland Pharma in the upcoming quarter?
Are there any pending regulatory approvals or clinical trial results for Gland Pharma that could trigger further institutional buying or selling activity?
What is the current valuation multiple of Gland Pharma relative to its peers, and does the 2.95% stake align with typical institutional rebalancing thresholds?


































